Core Viewpoint - Guangdong Jiaying Pharmaceutical Co., Ltd. is facing administrative penalties from the China Securities Regulatory Commission (CSRC) for failing to timely disclose related party transactions involving 220 million yuan [1][3][4] Group 1: Company Actions and Violations - Jiaying Pharmaceutical's chairman, Li Neng, is the actual controller of Hunan Yaojuneng Pharmaceutical Co., Ltd., which constitutes a related party [3] - From October 2024 to January 2025, Jiaying Pharmaceutical's subsidiary provided short-term loans to the related party, totaling 219.99 million yuan, which accounted for 28.83% of Jiaying Pharmaceutical's latest audited net assets [3][4] - The company did not follow the required procedures for related party transactions and failed to disclose these transactions in a timely manner [3][4] Group 2: Regulatory Response - The CSRC Guangdong Regulatory Bureau has determined that Jiaying Pharmaceutical's actions violate multiple provisions of the Securities Law, including failure to disclose related party transactions [4] - Proposed penalties include a warning and a fine of 1.5 million yuan for Jiaying Pharmaceutical, 1.6 million yuan for Li Neng, 1 million yuan for Yu Yongping, and 800,000 yuan for Shi Junping [5]

Core Viewpoint - Jia Ying Pharmaceutical (002198.SZ) and its responsible persons received a warning and fines from the Guangdong Securities Regulatory Bureau due to failure to timely disclose related party transactions involving approximately 220 million yuan [2][4][6] Group 1: Regulatory Actions - The company and its executives, including Chairman Li Neng, were issued a warning and fines due to the undisclosed borrowing of 220 million yuan from a related party, Hunan Yao Juneng Pharmaceutical Co., Ltd. [2][4][6] - The borrowing occurred between October 2024 and January 2025, with amounts ranging from 40,000 to 59.99 million yuan, totaling approximately 170 million yuan in 2024 and 50 million yuan in January 2025 [4][6] - The total amount borrowed represented 28.83% of Jia Ying Pharmaceutical's latest audited net assets [4] Group 2: Internal Changes and Financial Performance - The company has experienced significant internal changes, including the transfer of 7% of shares from shareholder Chen Shaobin to Yang Tianhe, making Yang Tianhe the second-largest shareholder [7] - Li Neng was elected as chairman on August 23, 2024, with a three-year term, amidst a series of resignations from key positions, including the financial director [7][8] - Jia Ying Pharmaceutical's revenue has declined for two consecutive years, with a 19.11% drop in 2023 and a further 29.46% decline in 2024, resulting in revenues of 533 million yuan and 376 million yuan, respectively [8] - The company's net profit also decreased significantly, with a 21.88% drop in 2023 and a 39.94% drop in 2024, leading to net profits of 34 million yuan and 21 million yuan, respectively [8] - In the first quarter of 2024, the company reported a revenue of 122 million yuan, a year-on-year increase of 28.83%, and a net profit of 15 million yuan, reflecting a significant growth of 197.23% [8]

Core Viewpoint - The chairman of Jiaying Pharmaceutical, Li Neng, is facing penalties for misappropriating company funds shortly after taking office, highlighting governance issues within the company [1][2][3]. Group 1: Regulatory Actions - Jiaying Pharmaceutical received an administrative penalty notice from the Guangdong Securities Regulatory Bureau, with potential fines amounting to 1.5 million yuan for the company and additional fines for Li Neng and other responsible parties [1][3]. - The investigation revealed that from October 2024 to January 2025, Jiaying Pharmaceutical's subsidiary provided short-term loans to a company controlled by Li Neng, totaling 220 million yuan, which constituted 28.83% of the company's audited net assets at that time [1][3]. Group 2: Company Background - Jiaying Pharmaceutical, established in 2003 and listed in December 2007, specializes in the research, production, and sales of traditional Chinese medicine, with a focus on proprietary and patented products [8]. - The company has experienced frequent changes in its major shareholders over the years, with the most recent change occurring in 2023 when Dongfang Securities became the largest shareholder [8]. Group 3: Financial Performance - The company's financial performance has been lackluster, with net profits showing minimal growth over the past five years, including a net profit of only 15.4 million yuan in the first quarter of 2025, despite a nearly twofold increase compared to the previous year [1][8]. - From 2020 to 2024, Jiaying Pharmaceutical's net profits were 19.84 million yuan, 1.48 million yuan, 43.93 million yuan, 34.32 million yuan, and 20.61 million yuan, indicating overall stagnant performance [8][9].

证券代码：002198 证券简称：嘉应制药 公告编号：2025-043 二、股份回购进展情况 截至2025年7月31日，公司通过股票回购专用证券账户以集中竞价方式已累 计回购公司股份9,240,000股，占公司目前总股本的1.8206%，回购的最高成交价 格为7.04元/股，最低成交价格为5.96元/股，成交总金额为62,258,006元（不含交 易费用）。 本次回购股份资金来源为公司自有资金，回购价格未超过回购方案中拟定的 价格上限9.80元/股。本次回购符合相关法律法规及公司既定回购股份方案的要求。 三、其他事项说明 公司将在回购期限内根据市场情况择机作出回购决策并予以实施，同时将根 据回购事项进展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 广东嘉应制药股份有限公司董事会 广东嘉应制药股份有限公司 本公司及董事会保证本公告内容的真实、准确和完整，不存在虚假记载、误导 性陈述或者重大遗漏。 一、回购方案的主要内容 广东嘉应制药股份有限公司（以下简称"公司"）于2024年12月12日召开的 第七届董事会第四次临时会议，审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有资金以集 ...

Core Viewpoint - Guangdong Jiaying Pharmaceutical (002198) has been penalized by regulatory authorities for violations related to related-party transactions and information disclosure [2][5][8]. Group 1: Regulatory Penalties - Jiaying Pharmaceutical was informed of an administrative penalty, including a fine of 1.5 million yuan and warnings for its chairman and other executives, totaling nearly 5 million yuan in penalties [5][6]. - The company engaged in short-term fund borrowing of 219 million yuan to a related party, Yao Juneng, without following the required approval and disclosure procedures [2][7]. Group 2: Financial Performance - In 2024, Jiaying Pharmaceutical reported a revenue of 376 million yuan, a year-on-year decline of 29.46%, marking the second consecutive year of double-digit revenue decline [7]. - The net profit attributable to shareholders was 20.61 million yuan, down 39.94% from the previous year, with a net profit margin dropping from 6.44% in 2023 to 5.48% in 2024 [7]. Group 3: Corporate Governance Issues - The company has faced multiple regulatory warnings in the past for information disclosure violations, indicating ongoing governance issues [8]. - Frequent changes in senior management have raised concerns, with the current chairman, Li Neng, assuming his role shortly before the company faced these violations [8][10]. Group 4: Market Position and Challenges - Jiaying Pharmaceutical has struggled with weak profitability since its listing, with core products experiencing significant sales declines due to national price adjustments in traditional Chinese medicine [9]. - The company has undergone multiple ownership changes, with the current major shareholder being Dongfang Securities, which acquired shares through debt settlement [10]. Group 5: Future Risks - The company and its second-largest shareholder, Yao Juneng, are facing challenges in a highly competitive market, with potential risks of delisting if regulatory issues persist [11].

证券日报网讯8月4日晚间，嘉应制药（002198）发布公告称，截至2025年7月31日，公司通过股票回购 专用证券账户以集中竞价方式已累计回购公司股份9，240，000股，占公司目前总股本的1.8206%。 ...

（文章来源：每日经济新闻） 嘉应制药（SZ 002198，收盘价：6.94元）8月4日晚间发布公告称，截至2025年7月31日，公司通过股票 回购专用证券账户以集中竞价方式已累计回购公司股份924万股，占公司目前总股本的1.8206%，回购 的最高成交价格为7.04元/股，最低成交价格为5.96元/股，成交总金额约为6226万元。 2024年1至12月份，嘉应制药的营业收入构成为：医药行业占比99.8%，其他业务占比0.2%。 ...

证券代码：002198 证券简称：嘉应制药 公告编号：2025-043 广东嘉应制药股份有限公司 关于股份回购进展情况的公告 2025年1月3日，公司首次实施了股份回购。根据《深圳证券交易所上市公司 自律监管指引第9号——回购股份》等相关规定，公司在回购期间应当在每个月 的前三个交易日内披露截至上月末的回购进展情况。现将公司截至上月末的回购 进展情况公告如下： 二、股份回购进展情况 截至2025年7月31日，公司通过股票回购专用证券账户以集中竞价方式已累 计回购公司股份9,240,000股，占公司目前总股本的1.8206%，回购的最高成交价 格为7.04元/股，最低成交价格为5.96元/股，成交总金额为62,258,006元（不含交 易费用）。 本次回购股份资金来源为公司自有资金，回购价格未超过回购方案中拟定的 价格上限9.80元/股。本次回购符合相关法律法规及公司既定回购股份方案的要求。 三、其他事项说明 公司将在回购期限内根据市场情况择机作出回购决策并予以实施，同时将根 据回购事项进展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 本公司及董事会保证本公告内容的真实、准确和完整，不存在 ...

Core Viewpoint - Jia Ying Pharmaceutical is facing administrative penalties from the China Securities Regulatory Commission for violations related to information disclosure and improper related-party transactions [3][4] Group 1: Regulatory Actions - The company and its key personnel, including Chairman Li Neng, General Manager You Yongping, and former CFO Shi Junping, received a notice of administrative penalties for failing to disclose related-party transactions properly [3][4] - The Guangdong Regulatory Bureau plans to impose a fine of 1.5 million yuan on Jia Ying Pharmaceutical and varying fines on the individuals involved, with Li Neng facing a fine of 160,000 yuan [4] Group 2: Related-Party Transactions - Between October 2024 and January 2025, Jia Ying Pharmaceutical's subsidiary provided short-term loans to its related party, Hunan Yao Juneng, totaling 220 million yuan, which accounted for 28.83% of the company's audited net assets at that time [3] - The transactions were not conducted in accordance with the required approval procedures and were not disclosed in a timely manner [3] Group 3: Company Background - Jia Ying Pharmaceutical, established in 2003 and listed on the Shenzhen Stock Exchange in 2007, specializes in the research, production, and sales of traditional Chinese medicine [6] - The company has total assets exceeding 1 billion yuan and a market capitalization of nearly 3 billion yuan [6] Group 4: Financial Performance - In 2024, Jia Ying Pharmaceutical reported revenue of 376 million yuan, a year-on-year decrease of 29.46%, and a net profit of 20.61 million yuan, down 39.94% [7] - In the first quarter of 2025, the company saw a revenue increase of 28.83% year-on-year, reaching 122 million yuan, and a net profit increase of 197.23%, totaling 15.40 million yuan [7]

Core Viewpoint - On August 1, 2023, Jiaying Pharmaceutical (002198) received an administrative penalty notice from the Guangdong Regulatory Bureau of the China Securities Regulatory Commission (CSRC) for failing to timely disclose 220 million yuan in related party fund borrowing, resulting in fines for the company and its responsible persons [1][2]. Group 1: Administrative Penalties - Jiaying Pharmaceutical was fined 1.5 million yuan, while its chairman Li Neng was fined 160,000 yuan, general manager You Yongping 100,000 yuan, and former financial director Shi Junping 80,000 yuan, totaling 4.9 million yuan [1][2]. - The violations involved non-operating fund transactions that were not disclosed until the 2024 annual report, constituting a breach of the Securities Law [2]. Group 2: Company Background - Jiaying Pharmaceutical is a traditional Chinese medicine manufacturer established in 2003, with R&D, production, and sales bases in Changsha, Hunan Province, and Meizhou, Guangdong Province [3][4]. - As of August 4, 2025, the company's total market value was 3.517 billion yuan, with a product portfolio that includes 70 approved drug varieties across various therapeutic areas [4].